Trial reportBMC endocrine disorders2025
Safety and efficacy of topical melatonin add-on in healing of diabetic foot ulcer: a double blind, randomized clinical trial.
Trial report in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDiabetic foot ulcer (DFU) is one of the disturbing complications associated with diabetes that influence the quality of life. Melatonin with stimulating of collagen production, emerges as a promising candidate for chronic wound treatment such as diabetic foot ulcer (DFU). This clinical trial investigates the efficacy of a novel topical melatonin hydrogel in promoting the healing process of DFUs.
methodsTo assess the efficacy of the topical hydrogel containing 1% melatonin on grades 1 and 2 DFUs, a double-blind, randomized, placebo-controlled trial was designed. Subjects were randomly assigned to two groups: an experimental group receiving melatonin (1 mg/cm²) and a control group receiving a placebo. The hydrogel was applied at night for two months. The number, grade, size, and healing proportion of ulcers were assessed at baseline, after one month (day 30), and at the end of the study (day 60).
resultsThirty patients with a total of fifty-three ulcers completed the study. The melatonin group demonstrated a significant decrease in ulcer number and severity grade, along with an increase in healing proportion compared to the placebo group (p < 0.05). The reduction in ulcer size in the melatonin group was approximately twofold greater in compare with the placebo (mean reduction: -2.7 ± 0.4 cm² vs. -1.34 ± 0.39 cm²; p-value: 0.08). Patients on melatonin with HbA1c levels ≤ 8% or with new-onset ulcers (≤ 3 weeks old) experienced statistically significant reductions in ulcer size (p = 0.02 and 0.04, respectively).
conclusionsTopical 1% melatonin hydrogel demonstrated efficacy and safety in reducing the number, grade, and size of DFUs when used as a complementary therapy alongside standard ulcer care. This approach may help prevent complications associated with non-healing ulcers thereby improving patients’ quality of life and functional independence.
trial registration(Trial Id:54495; Iranian registry of clinical trial identifier code: IRCT20200220046560N1; registration date: 2021-04−09).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.